Yamo Pharmaceuticals Advances Autism Drug to Phase 3
The FDA granted Fast Track status to L1-79, a new medication targeting core neurological symptoms of autism.
Updated on Oct. 26, 2026 in Autism
Live Poll
Should the FDA prioritize approving drugs that target the underlying neurological core features of autism?
Yamo Pharmaceuticals has advanced its investigational drug L1-79 to Phase 3 clinical trials following successful earlier testing. The medication, which has received Fast Track designation from the FDA, is designed to treat the core neurological features of autism spectrum disorder.
Why it matters
The treatment aims to balance hyperactive chemical pathways that contribute to social withdrawal and sensory overload. If successful, L1-79 may become the first FDA-approved therapy specifically targeting these core symptoms of autism.
Phase 2 clinical trials for L1-79 involved 116 patients to evaluate its potential as a selective inhibitor of tyrosine hydroxylase. The upcoming Phase 3 study will feature a 16-week randomized, double-blind treatment period.
The players
Yamo Pharmaceuticals
Founded in 2015, this privately held company specializes in developing novel treatments for autism spectrum disorder.
FDA
The U.S. Food and Drug Administration is the federal agency responsible for regulating medications and granting Fast Track designations for drug development.
The details
The drug functions by reducing the production of dopamine and norepinephrine to stabilize overactive brain pathways. Yamo Pharmaceuticals has received 6,000 inquiries for its clinical program from families across 90 countries.
Timeline
December 2015: The Turteltaub family considered starting Joshua on L1-79.
December 2026: Yamo Pharmaceuticals will meet with the FDA to finalize Phase 3 protocols.
Early 2027: Phase 3 clinical trials are expected to commence.
Health Landscape
Current treatment options for autism are limited to medications like aripiprazole and risperidone, which do not target the core neurological features of the condition. L1-79 represents a potential departure from these established options by addressing the underlying chemical pathway imbalances.
If approved, L1-79 could provide a new medical option for individuals struggling with sensory overload and social withdrawal symptoms. Patients should monitor future clinical trial results to see how this treatment might fit into their broader health routines.
The takeaway
L1-79 highlights a shift toward treating the root neurochemical drivers of autism rather than just addressing symptomatic behaviors. Families currently managing autism should remain updated on Phase 3 trial milestones as they approach early 2027.
Further reading
Learn more about the latest developments in Autism research and clinical interventions.
Source note: This article includes information reported by Mail Online.
Live Poll
Should the FDA prioritize approving drugs that target the underlying neurological core features of autism?
